請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/97029完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 李宗徽 | zh_TW |
| dc.contributor.advisor | Tzong-Huei Lee | en |
| dc.contributor.author | 張家豪 | zh_TW |
| dc.contributor.author | Chia-Hao Chang | en |
| dc.date.accessioned | 2025-02-25T16:33:22Z | - |
| dc.date.available | 2025-02-26 | - |
| dc.date.copyright | 2025-02-25 | - |
| dc.date.issued | 2025 | - |
| dc.date.submitted | 2025-02-17 | - |
| dc.identifier.citation | 1. Cowan, M. M. Plant products as antimicrobial agents. A S M 1999, 12 (4), 564−582.
2. Zerbe, P. Plants against cancer: towards green Taxol production through pathway discovery and metabolic engineering. aBIOTECH 2024, 5 (3), 394−402. 3. Raskin, I.; Ribnicky, D. M.; Komarnytsky, S.; Ilic, N.; Poulev, A.; Borisjuk, N.; et al. Plants and human health in the twenty-first century. Trends Biotechnol 2002, 20(12), 522−531. 4. David, B.; Wolfender, J. L.; Dias, D. A. The pharmaceutical industry and natural products: historical status and new trends. Phytochemistry Reviews 2014, 14 (2), 299−315. 5. Xu, Z.; Eichler, B.; Klausner, E. A.; Duffy-Matzner, J.; Zheng, W. Lead/drug discovery from natural resources. Molecules 2022, 27 (23), 8280. 6. Cragg, G. M.; Newman, D. J. Biodiversity: A continuing source of novel drug leads. Pure and Applied Chemistry 2005, 77 (1), 7−24. 7. Bernardini, S.; Tiezzi, A.; Laghezza Masci, V.; Ovidi, E. Natural products for human health: an historical overview of the drug discovery approaches. Nat Prod Res 2018, 32 (16), 1926−1950. 8. Zhang, Q. W.; Lin, L. G.; Ye, W. C. Techniques for extraction and isolation of natural products: a comprehensive review. Chin Med 2018, 13, 20. 9. Cragg, G. M.; Newman, D. M. Natural products A continuing source of novel drug leads. Biochim Biophys Acta 2013, 1830(6), 3670−3695. 10. Yuan, H.; Ma, Q.; Ye, L.; Piao, G. The traditional medicine and modern medicine from natural products. Molecules 2016, 21 (5), 559. 11. Fabricant, D. S.; Farnsworth, N. R. The value of plants used in traditional medicine for drug discovery. Environ Health Perspect 2001, 109, 69−75. 12. Liu, Z.; Guo, F.; Wang, Y.; Li, C.; Zhang, X.; Li, H.; et al. BATMAN-TCM: A bioinformatics analysis tool for molecular mechANism of traditional chinese medicine. Sci Rep 2016, 6, 21146. 13. Hamilton, G. R.; Baskett, F. T. In the arms of Morpheus the development of morphine for postoperative pain relief. Can J Anaesth 2000, 47(4), 367−374. 14. Dias, D. A.; Urban, S.; Roessner, U. A historical overview of natural products in drug discovery. Metabolites 2012, 2 (2), 303−336. 15. de Oliveira, A. R. M; Szczerbowski, D. Quinine 470 years of history, controversy and science development. Quim Nova 2009, 32(7), 1971−1974. 16. Kato, M.; Mizuno, K. Caffeine synthase and related methyltransferases in plants. Front Biosci 2004, 9, 1833−1842. 17. Hagel, J. M.; Facchini, P. J. Benzylisoquinoline alkaloid metabolism: a century of discovery and a brave new world. Plant Cell Physiol 2013, 54 (5), 647−672. 18. Wang, L. Z.; Syn, N.; Li, S.; Barathi, V. A.; Tong, L.; Neo, J.; et al. The penetration and distribution of topical atropine in animal ocular tissues. Acta Ophthalmol 2019, 97 (2), e238−e247. 19. Nett, R. S.; Lau, W.; Sattely, E. S. Discovery and engineering of colchicine alkaloid biosynthesis. Nature 2020, 584 (7819), 148−153. 20. Grzybowski, A. Cocaine and the eye: a historical overview. Ophthalmologica 2008, 222 (5), 296-301. 21. Bai, R.; Yao, C.; Zhong, Z.; Ge, J.; Bai, Z.; Ye, X.; et al. Discovery of natural anti-inflammatory alkaloids: Potential leads for the drug discovery for the treatment of inflammation. Eur J Med Chem 2021, 213, 113165. 22. Harvey, A. L. Natural products in drug discovery. Drug Discov Today 2008, 13 (19-20), 894−901. 23. Montinari, M. R.; Minelli, S.; De Caterina, R. The first 3500 years of aspirin history from its roots - A concise summary. Vascul Pharmacol 2019, 113, 1−8. 24. Atanasov, A. G.; Waltenberger, B.; Pferschy-Wenzig, E. M.; Linder, T.; Wawrosch, C.; Uhrin, P.; et al. Discovery and resupply of pharmacologically active plant-derived natural products: A review. Biotechnol Adv 2015, 33 (8), 1582−1614. 25. Luo, H.; Vong, C. T.; Chen, H.; Gao, Y.; Lyu, P.; Qiu, L.; et al. Naturally occurring anti-cancer compounds: shining from Chinese herbal medicine. Chin Med 2019, 14 (1), 48. 26. Wani, M. C. Plant antitumor agents VI. The isolation and structure of taxol a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 1972, 19, 2325−2326. 27. Suffness, M.; Douros, J. Current status of the NCI plant and animal product program. J Nat Prod 1982, 45 (1), 1−14. 28. Fabricant, D. S.; Farnsworth, N. R. The value of plants used in traditional medicine for drug discovery. Environ Health Perspect 2001, 109, 69−75. 29. Anand, K.; Kumar, V.; Prasher, I. B.; Sethi, M.; Raj, H.; Ranjan, H.; et al. Bioactive molecules from fungal endophytes and their applications in pharmaceutical industries: challenges and future scope. J Basic Microbiol 2023, 63 (7), 690−708. 30. Kingston, D. G. I.; Cassera, M. B. (2022). Antimalarial Natural Products. In: Kinghorn, A. D., Falk, H., Gibbons, S., Asakawa, Y., Liu, J. K., Dirsch, V. M. (eds) Antimalarial natural products. progress in the chemistry of organic natural products, vol 117. Springer, Cham. 31. Mayor, S. Tree that provides paclitaxel is put on list of endangered species. BMJ 2011, 343, d7411. 32. Canter, P. H.; Thomas, H.; Ernst, E. Bringing medicinal plants into cultivation: opportunities and challenges for biotechnology. Trends Biotechnol 2005, 23 (4), 180−185. 33. Demain, A. L.; Sanchez, S. Microbial drug discovery: 80 years of progress. J Antibiot (Tokyo) 2009, 62 (1), 5−16. 34. Hutchings, M. I.; Truman, A. W.; Wilkinson, B. Antibiotics: past, present and future. Curr Opin Microbiol 2019, 51, 72−80. 35. Waksman, S. A.; Schatz, A.; Reynolds, D. M. Production of antibiotic substances by actinomycetes. Ann N Y Acad Sci 2010, 1213, 112−124. 36. Umezawa, H. Kanamycin: its discovery. Ann N Y Acad Sci 1958, 76 (2), 20−26. 37. Wang, H.; Wang, L.; Fan, K.; Pan, G. Tetracycline natural products: discovery, biosynthesis and engineering. Chin J Nat Med 2022, 20 (10), 773−794. 38. Araten, A. H.; Brooks, R. S.; Choi, S. D. W.; Esguerra, L. L.; Savchyn, D.; Wu, E. J.; et al. Cephalosporin resistance, tolerance, and approaches to improve their activities. J Antibiot 2024, 77 (3), 135−146. 39. Tevyashova, A. N. Recent trends in synthesis of chloramphenicol new derivatives. Antibiotics 2021, 10 (4), 370. 40. Platon, V. M.; Dragoi, B.; Marin, L. Erythromycin formulations-A journey to advanced drug delivery. Pharmaceutics 2022, 14 (10), 2180. 41. Katz, L.; Baltz, R. H. Natural product discovery: past, present, and future. J Ind Microbiol Biotechnol 2016, 43 (2-3), 155−176. 42. Atanasov, A. G.; Zotchev, S. B.; Dirsch, V. M. Natural products in drug discovery: advances and opportunities. Nat Rev Drug Discov 2021, 20 (3), 200−216. 43. Newman, D. J.; Cragg, G. M. Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. J Nat Prod 2020, 83 (3), 770−803. 44. Newman, D. J.; Cragg, G. M.; Snader, K. M. Natural products as sources of new drugs over the period 1981-2002. J Nat Prod 2003, 66(7), 1022−1037. 45. Chopra, B.; Dhingra, A. K. Natural products: A lead for drug discovery and development. Phytother Res 2021, 35 (9), 4660−4702. 46. Hardoim, P. R.; van Overbeek, L. S.; Berg, G.; Pirttila, A. M.; Compant, S.; Campisano, A.; et al. The hidden world within plants: ecological and evolutionary considerations for defining functioning of microbial endophytes. Microbiol Mol Biol Rev 2015, 79 (3), 293−320. 47. Strobel, G.; Daisy, B. Bioprospecting for microbial endophytes and their natural products. Microbiol Mol Biol Rev 2003, 67 (4), 491−502. 48. Rodriguez, R. J.; White, J. F., Jr.; Arnold, A. E.; Redman, R. S. Fungal endophytes: diversity and functional roles. New Phytol 2009, 182 (2), 314−330. 49. Tan, R. X.; Zou, W. X. Endophytes: A rich source of functional metabolites. Nat Prod Rep 2001, 18 (4), 448−459. 50. Nisa, H.; Kamili, A. N.; Nawchoo, I. A.; Shafi, S.; Shameem, N.; Bandh, S. A. Fungal endophytes as prolific source of phytochemicals and other bioactive natural products: A review. Microb Pathog 2015, 82, 50−59. 51. Brakhage, A. A.; Schroeckh, V. Fungal secondary metabolites - Strategies to activate silent gene clusters. Fungal Genet Biol 2011, 48 (1), 15−22. 52. Jia, M.; Chen, L.; Xin, H. L.; Zheng, C. J.; Rahman, K.; Han, T.; et al. A friendly relationship between endophytic fungi and medicinal plants: A systematic review. Front Microbiol 2016, 7, 906. 53. Okada, B. K.; Seyedsayamdost, M. R. Antibiotic dialogues: induction of silent biosynthetic gene clusters by exogenous small molecules. FEMS Microbiol Rev 2017, 41 (1), 19−33. 54. Pfannenstiel, B. T.; Keller, N. P. On top of biosynthetic gene clusters: How epigenetic machinery influences secondary metabolism in fungi. Biotechnol Adv 2019, 37 (6), 107345. 55. Brakhage, A. A.; Schroeckh, V. Fungal secondary metabolites - Strategies to activate silent gene clusters. Fungal Genet Biol 2011, 48 (1), 15−22. 56. Arnold, A. E.; Lutzoni, F. Diversity and host range of foliar fungal endophytes: are tropical leaves biodiversity hotspots? Ecology 2007, 88 (3), 541−549. 57. Singh, A.; Singh, D. K.; Kharwar, R. N.; White, J. F.; Gond, S. K. Fungal endophytes as efficient sources of plant-derived bioactive compounds and their prospective applications in natural product drug discovery: insights, avenues, and challenges. Microorganisms 2021, 9 (1), 197. 58. Zhang, X. Y.; Tan, X. M.; Yu, M.; Yang, J.; Sun, B. D.; Qin, J. C.; et al. Bioactive metabolites from the desert plant-associated endophytic fungus Chaetomium globosum (Chaetomiaceae). Phytochemistry 2021, 185, 112701. 59. Giddings, L. A.; Newman, D. J. Extremophilic fungi from marine environments: underexplored sources of antitumor, anti-infective and other biologically active agents. Mar Drugs 2022, 20 (1), 62. 60. Qin, G. F.; Zhang, X.; Zhu, F.; Huo, Z. Q.; Yao, Q. Q.; Feng, Q.; et al. MS/MS-based molecular networking: An efficient approach for natural products dereplication. Molecules 2022, 28 (1), 157. 61. Palma Esposito, F.; Giugliano, R.; Della Sala, G.; Vitale, G. A.; Buonocore, C.; Ausuri, J.; et al. Combining OSMAC approach and untargeted metabolomics for the identification of new glycolipids with potent antiviral activity produced by a marine Rhodococcus. Int J Mol Sci 2021, 22 (16), 9055. 62. Schuller, A.; Studt-Reinhold, L.; Strauss, J. How to completely squeeze a fungus-advanced genome mining tools for novel bioactive substances. Pharmaceutics 2022, 14 (9), 1837. 63. Reyes, F.; Bills, G. F.; Duran-Patron, R. Editorial: Strategies for the discovery of fungal natural products. Front Microbiol 2022, 13, 897756. 64. Takahashi, J. A.; Teles, A. P. C.; Bracarense, A. D. P.; Gomes, D. C. Classical and epigenetic approaches to metabolite diversification in filamentous fungi. Phytochemistry Reviews 2013, 12 (4), 773−789. 65. Romano, S.; Jackson, S. A.; Patry, S.; Dobson, A. D. W. Extending the "one strain many compounds" (OSMAC) principle to marine microorganisms. Mar Drugs 2018, 16 (7), 244. 66. Pinedo-Rivilla, C.; Aleu, J.; Duran-Patron, R. Cryptic metabolites from marine-derived microorganisms using OSMAC and epigenetic approaches. Mar Drugs 2022, 20 (2), 84. 67. Pan, R.; Bai, X.; Chen, J.; Zhang, H.; Wang, H. Exploring structural diversity of microbe secondary metabolites using OSMAC strategy: A literature review. Front Microbiol 2019, 10, 294. 68. Li, Y.; Gong, N.; Zhou, L.; Yang, Z.; Zhang, H.; Gu, Y.; et al. OSMAC-based discovery and biosynthetic gene clusters analysis of secondary metabolites from marine-derived Streptomyces globisporus SCSIO LCY30. Mar Drugs 2023, 22 (1), 21. 69. Hu, Z.; Ye, Y.; Zhang, Y. Large-scale culture as a complementary and practical method for discovering natural products with novel skeletons. Nat Prod Rep 2021, 38 (10), 1775−1793. 70. Schüller, A.; Studt-Reinhold, L.; Strauss, J. How to completely squeeze a fungus-advanced genome mining tools for novel bioactive substances. Pharmaceutics 2022, 14(9), 1837. 71. Le Loarer, A.; Dufosse, L.; Bignon, J.; Frederich, M.; Ledoux, A.; Fouillaud, M.; et al. OSMAC method to assess impact of culture parameters on metabolomic diversity and biological activity of marine-derived actinobacteria. Mar Drugs 2023, 22 (1), 23. 72. Hernandez, A.; Nguyen, L. T.; Dhakal, R.; Murphy, B. T. The need to innovate sample collection and library generation in microbial drug discovery: a focus on academia. Nat Prod Rep 2021, 38 (2), 292−300. 73. Johnson, A. R.; Carlson, E. E. Collision-induced dissociation mass spectrometry: a powerful tool for natural product structure elucidation. Anal Chem 2015, 87 (21), 10668−10678. 74. Lachance, H.; Wetzel, S.; Kumar, K.; Waldmann, H. Charting, navigating, and populating natural product chemical space for drug discovery. J Med Chem 2012, 55 (13), 5989−6001. 75. Logan, T. M.; Murali, N.; Wang, G.; Jolivet, C. Application of a high-resolution superconducting NMR probe in natural product structure determination. Magnetic Resonance in Chemistry 1999, 37 (7), 512−515. 76. Brunger, A. T.; Adams, P. D.; Clore, G. M.; DeLano, W. L.; Gros, P.; Grosse-Kunstleve, R. W.; et al. Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr D Biol Crystallogr 1998, 54, 905−921. 77. Larsen, T. O.; Petersen, B. O.; Duus, J. O.; Sorensen, D.; Frisvad, J. C.; Hansen, M. E. Discovery of new natural products by application of X-hitting, a novel algorithm for automated comparison of full UV spectra, combined with structural determination by NMR spectroscopy. 2005, 68(6), 871−874. 78. Cozzolino, D. Near infrared spectroscopy in natural products analysis. Planta Med 2009, 75 (7), 746−756. 79. Lee, M. S.; Kerns, E. H. LC/MS applications in drug development. Mass Spectrometry Reviews 1999, 18 (3-4), 187−279. 80. Ramos, A. E. F.; Evanno, L.; Poupon, E.; Champy, P.; Beniddir, M. A. Natural products targeting strategies involving molecular networking: Different manners, one goal. Nat Prod Rep 2019, 36 (7), 960−980. 81. Allard, P. M.; Peresse, T.; Bisson, J.; Gindro, K.; Marcourt, L.; Pham, V. C.; et al. Integration of molecular networking and in-silico MS/MS fragmentation for natural products dereplication. Anal Chem 2016, 88 (6), 3317−3323. 82. Yang, J. Y.; Sanchez, L. M.; Rath, C. M.; Liu, X.; Boudreau, P. D.; Bruns, N.; Glukhov, E.; Wodtke, A.; de Felicio, R.; Fenner, A.; et al. Molecular networking as a dereplication strategy. J Nat Prod 2013, 76 (9), 1686−1699. 83. Chervin, J.; Perio, P.; Martins-Froment, N.; Pharkeovilay, C.; Reybier, K.; Nepveu, F.; et al. Dereplication of natural products from complex extracts by regression analysis and molecular networking: case study of redox-active compounds from Viola alba subsp. dehnhardtii. Metabolomics 2017, 13 (8), 96. 84. Olivon, F.; Allard, P. M.; Koval, A.; Righi, D.; Genta-Jouve, G.; Neyts, J.; et al. Bioactive natural products prioritization using massive multi-informational molecular networks. ACS Chem Biol 2017, 12 (10), 2644−2651. 85. Quinn, R. A.; Nothias, L. F.; Vining, O.; Meehan, M.; Esquenazi, E.; Dorrestein, P. C. Molecular networking as a drug discovery, drug metabolism, and precision medicine strategy. Trends Pharmacol Sci 2017, 38 (2), 143−154. 86. Kuo, T. H.; Huang, H. C.; Hsu, C. C. Mass spectrometry imaging guided molecular networking to expedite discovery and structural analysis of agarwood natural products. Anal Chim Acta 2019, 1080, 95−103. 87. Qin, G. F.; Zhang, X.; Zhu, F.; Huo, Z. Q.; Yao, Q. Q.; Feng, Q.; et al. MS/MS-based molecular networking: An efficient approach for natural products dereplication. Molecules 2022, 28 (1), 157. 88. Baskiyar, S.; Ren, C.; Heck, K. L.; Hall, A. M.; Gulfam, M.; Packer, S.; et al. Bioactive natural products identification using automation of molecular networking software. J Chem Inf Model 2022, 62 (24), 6378−6385. 89. Zhang, F.; Zhao, M.; Braun, D. R.; Ericksen, S. S.; Piotrowski, J. S.; Nelson, J.; et al. A marine microbiome antifungal targets urgent-threat drug-resistant fungi. Science 2020, 370 (6519), 974-+. 90. Murray, C. J. L.; Ikuta, K. S.; Sharara, F.; Swetschinski, L.; Aguilar, G. R.; Gray, A.; et al. Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis. Lancet 2022, 399 (10325), 629−655. 91. Crofts, T. S.; Sontha, P.; King, A. O.; Wang, B.; Biddy, B. A.; Zanolli, N.; et al. Discovery and characterization of a nitroreductase capable of conferring bacterial resistance to chloramphenicol. Cell Chem Biol 2019, 26 (4), 559−570. 92. Lam, S. J.; O'Brien-Simpson, N. M.; Pantarat, N.; Sulistio, A.; Wong, E. H.; Chen, Y. Y.; et al. Combating multidrug-resistant Gram-negative bacteria with structurally nanoengineered antimicrobial peptide polymers. Nat Microbiol 2016, 1 (11), 16162. 93. Hui, K. F.; Tam, K. P.; Chiang, A. K. S. Therapeutic strategies against Epstein-Barr Virus-associated cancers using proteasome inhibitors. Viruses 2017, 9 (11), 352. 94. Usha, M. K.; Jahan, J. A.; Islam, S. R. U.; Begum, F.; Ahsan, C. R.; Yasmin, M. Evaluation of plasma Epstein-Barr virus DNA as a biomarker for Epstein-Barr virus-associated Hodgkin lymphoma. SAGE Open Med 2021, 9, 20503121211054991. 95. James, J. A; Harley, J. B.; Scofield R. H. Epstein–Barr virus and systemic lupus erythematosus. Curr Rheumatol Rev 2006, 18(5), 462−467. 96. Contreras-Chavez, P.; Anampa-Guzman, A.; Gaznabi, S.; Lansigan, F. Epstein-Barr Virus infection-associated hemophagocytic lymphohistiocytosis. Cureus 2020, 12 (4), e7563. 97. Nishio, M.; Saito, M.; Yoshimori, M.; Kumaki, Y.; Ohashi, A.; Susaki, E.; et al. Clinical significance of anti-Epstein-Barr virus antibodies in systemic chronic active Epstein-Barr virus disease. Front Microbiol 2023, 14, 1320292. 98. Kerr, J. R. Epstein-Barr virus (EBV) reactivation and therapeutic inhibitors. J Clin Pathol 2019, 72 (10), 651-658. 99. Chang, C. H.; Lee, Y. C.; Hsiao, G.; Chang, L. K.; Chi, W. C.; Cheng, Y. C.; et al. Anti-Epstein-Barr Viral agents from the medicinal herb-derived fungus Alternaria alstroemeriae Km2286. J Nat Prod 2022, 85 (11), 2667−2674. 100. Chang, C. H.; Hsiao, G.; Wang, S. W.; Yen, J. Y.; Huang, S. J.; Chi, W. C.; et al. Chemical constituents from the medicinal herb-derived fungus Chaetomium globosum Km1226. Bot Stud 2023, 64 (1), 34. 101. Maresca, B.; Lambowitz, A. M.; Kumar, V. B.; Grant, G. A.; Kobayashi, G. S.; Medoff, G. Role of cysteine in regulating morphogenesis and mitochondrial activity in the dimorphic fungus Histoplasma capsulatum. PNAS 1981, 78 (7), 4596−4600. 102. Kahlos, K; Tikka, V. H. Antifungal activity of cysteine, its effect on C-21 oxygenated lanosterol derivatives and other lipids in Inonotus obliquus, in vitro. Appl Microbiol Biotechnol 1994, 42 (2-3), 385390. 103. Liu, Z. H.; Yang, Q.; Ma, J. A heat shock protein gene (hsp22.4) from Chaetomium globosum confers heat and Na2CO3 tolerance to yeast. Appl Microbiol Biotechnol 2007, 77 (4), 901−908. 104. Provost, N. B.; Shi, C.; She, Y. M.; Cyr, T. D.; Miller, J. D. Characterization of an antigenic chitosanase from the cellulolytic fungus Chaetomium globosum. Med Mycol 2013, 51 (3), 290−299. 105. Tian, Y.; Li, Y. A Review on Bioactive Compounds from marine-derived Chaetomium species. J Microbiol Biotechnol 2022, 32 (5), 541−550. 106. Abou Alhamed, M. F.; Shebany, Y. M. Endophytic Chaetomium globosum enhances maize seedling copper stress tolerance. Plant Biol 2012, 14 (5), 859−863. 107. Cullen, d.; Berbee, F. M.; Andrews, J. H. Chaetomium globosum antagonizes the apple scab pathogen, Venturia inaequalis, under field conditions. CAN J BOT Journal 1984, 62 (9), 1814−1818. 108. Zhang, Q.; Li, H. Q.; Zong, S. C.; Gao, J. M.; Zhang, A. L. Chemical and bioactive diversities of the genus Chaetomium secondary metabolites. Mini-Rev Med Chem 2012, 12 (2), 127−148. 109. Fatima, N.; Muhammad, S. A.; Khan, I.; Qazi, M. A.; Shahzadi, I.; Mumtaz, A.; et al. Chaetomium endophytes: A repository of pharmacologically active metabolites. Acta Physiologiae Plantarum 2016, 38 (6), 136. 110. Chen, J.; Zhang, W.; Guo, Q.; Yu, W.; Zhang, Y.; He, B. Bioactivities and future perspectives of chaetoglobosins. Evid Based Complement Alternat Med 2020, 2020, 8574084. 111. Dwibedi, V.; Rath, S. K.; Jain, S.; Martinez-Argueta, N.; Prakash, R.; Saxena, S.; et al. Key insights into secondary metabolites from various Chaetomium species. Appl Microbiol Biotechnol 2023, 107 (4), 1077−1093. 112. Sekita, S.; Yoshihira, K.; Natori, S.; Kuwano, H. Structures of chaetoglobosin A and B, cytotoxic metabolites of Chaetomium globosum. Tetrahedron Lett 1973, 23, 2019−2112. 113. Umeda, M.; Ohtsubo, K.; Saito, M.; Sekita, S.; Yoshihira, K.; Natori, S.; et al. Cytotoxicity of new cytochalasans from Chaetomium globosum. Experientia 1975, 31, 435−438. 114. Sekita, S.; Yoshihira, K.; Natori, S.; Kuwano, K. Structures of chaetoglobosins C, D, E, and F, cytotoxic indol-3-yl- [13]cytochalasans from Chaetomium globosum. Tetrahedron Lett 1976, 17, 1351−1354. 115. Sekita, S.; Yoshihira, K.; Natori, S.; Kuwano, H. Chaetoglobosins G and J, cytotoxic indol- 3-yl[13]-cytochalasans from Chaetomium globosum. Tetrahedron Lett 1977, 32, 2771−2774. 116. Probst, A.; Tamm, C. 19-O-Acetylchaetoglobosin B and 19-O-acetylchaetoglobosin D, two new metabolites of Chaetomium globosum. Helv Chim Acta 1981, 64, 2056−2064. 117. Jiao, W. X.; Feng, Y. J.; Blunt, J. W.; Cole, A. L. J.; Munro, M. H. G. Chaetoglobosins Q, R, and T, three further new metabolites from Chaetomium globosum. J Nat Prod 2004, 67, 1722−1725. 118. Ding, G.; Song, Y. C.; Chen, J. R.; Xu, C.; Ge, H. M.; Wang, X. T.; et al. Chaetoglobosin U, a cytochalasan alkaloid from endophyfle Chaetomium globosum IFB-E019. J Nat Prod 2006, 69, 302−304. 119. Cui, C. M.; Li, X. M.; Li,, C. S.; Proksch, P.; Wang, B. G. Cytoglobosins A-G, cytochalasans from a marine-derived endophytic fungus, Chaetomium globosum QEN-14. J Nat Prod 2010, 73, 729−733. 120. Zhang, J.; Ge, H. M.; Jiao, R. H.; Li, J.; Peng, H.; Wang, Y. R.; et al. Cytotoxic chaetoglobosins from the endophyte Chaetomium globosum. Planta Med 2010, 76 (16), 1910−1914. 121. Ge, H. M.; Yan, W.; Guo, Z. K.; Luo, Q. O.; Feng, R.; Zang, L. Y.; et al. Precursor-directed fungal generation of novel halogenated chaetoglobosins with more preferable immunosuppressive action. Chem Commun 2011, 47 (8), 2321−2323. 122. Wang, Y.; Xu, L.; Ren, W.; Zhao, D.; Zhu, Y.; Wu, X. Bioactive metabolites from Chaetomium globosum L18, an endophytic fungus in the medicinal plant Curcuma wenyujin. Phytomedicine 2012, 19 (3-4), 364−368. 123. Xue, M.; Zhang, Q.; Gao, J. M.; Li, H.; Tian, J. M.; Pescitelli, G. Chaetoglobosin Vb from endophytic Chaetomium globosum: absolute configuration of chaetoglobosins. Chirality 2012, 24 (8), 668−674. 124. Zheng, Q. C.; Kong, M. Z.; Zhao, Q.; Chen, G. D.; Tian, H. Y.; Li, X. X.; et al. Chaetoglobosin Y, a new cytochalasan from Chaetomium globosum. Fitoterapia 2014, 93, 126−131. 125. Chen, C.; Zhu, H.; Li, X. N.; Yang, J.; Wang, J.; Li, G.; et al. Armochaeglobines A and B, two new indole-based alkaloids from the arthropod-derived fungus Chaetomium globosum. Org Lett 2015, 17 (3), 644−647. 126. Chen, C.; Wang, J.; Liu, J.; Zhu, H.; Sun, B.; Wang, J.; et al. Armochaetoglobins A-J: Cytochalasan alkaloids from Chaetomium globosum TW1-1, a fungus derived from the terrestrial arthropod Armadillidium vulgare. J Nat Prod 2015, 78 (6), 1193−1201. 127. Chen, C.; Zhu, H.; Wang, J.; Yang, J.; Li, X. N.; Wang, J.; et al. Armochaetoglobins K–R, anti‐hiv pyrrole‐based cytochalasans from Chaetomium globosum TW1‐1. European Journal of Organic Chemistry 2015, 2015 (14), 3086−3094. 128. Zhang, Z.; Min, X.; Huang, J.; Zhong, Y.; Wu, Y.; Li, X.; et al. Cytoglobosins H and I, new antiproliferative cytochalasans from deep-sea-derived fungus Chaetomium globosum. Mar Drugs 2016, 14 (12), 233. 129. Jiang, T.; Wang, M.; Li, L.; Si, J.; Song, B.; Zhou, C.; et al. Overexpression of the global regulator LaeA in Chaetomium globosum leads to the biosynthesis of chaetoglobosin Z. J Nat Prod 2016, 79 (10), 2487−2494. 130. Li, W.; Yang, X.; Yang, Y.; Duang, R.; Chen, G.; Li, X.; et al. Anti-phytopathogen, multi-target acetylcholinesterase inhibitory and antioxidant activities of metabolites from endophytic Chaetomium globosum. Nat Prod Res 2016, 30 (22), 2616−2619. 131. Yan, X.; Wang, L. J.; Wu, Z.; Wu, Y. L.; Liu, X. X.; Chang, F. R.; et al. New on-line separation workflow of microbial metabolites via hyphenation of analytical and preparative comprehensive two-dimensional liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 2016, 1033, 1−8. 132. Chen, C. M.; Tong, Q. Y.; Zhu, H. C.; Tan, D. D.; Zhang, J. W.; Xue, Y. B.; et al. Nine new cytochalasan alkaloids from Chaetomium globosum TW1-1 (Ascomycota, Sordariales). Sci Rep 2016, 6, 18711. 133. Gao, W.; Sun, W.; Li, F.; Chai, C.; He, Y.; Wang, J.; et al. Armochaetoglasins A-I: Cytochalasan alkaloids from fermentation broth of Chaetomium globosum TW1-1 by feeding L-tyrosine. Phytochemistry 2018, 156, 106−115. 134. Yang, M. H.; Gu, M. L.; Han, C.; Guo, X. J.; Yin, G. P.; Yu, P.; et al. Aureochaeglobosins A-C, three [4 + 2] adducts of chaetoglobosin and aureonitol derivatives from Chaetomium globosum. Org Lett 2018, 20 (11), 3345−3348. 135. Ruan, B. H.; Yu, Z. F.; Yang, X. Q.; Yang, Y. B.; Hu, M.; Zhang, Z. X.; et al. New bioactive compounds from aquatic endophyte Chaetomium globosum. Nat Prod Res 2018, 32 (9), 1050−1055. 136. Gao, W.; He, Y.; Li, F.; Chai, C.; Zhang, J.; Guo, J.; et al. Antibacterial activity against drug-resistant microbial pathogens of cytochalasan alkaloids from the arthropod-associated fungus Chaetomium globosum TW1-1. Bioorg Chem 2019, 83, 98−104. 137. Qi, J.; Jiang, L.; Zhao, P.; Chen, H.; Jia, X.; Zhao, L.; et al. Chaetoglobosins and azaphilones from Chaetomium globosum associated with Apostichopus japonicus. Appl Microbiol Biotechnol 2020, 104 (4), 1545−1553. 138. Luo, X. W.; Gao, C. H.; Lu, H. M.; Wang, J. M.; Su, Z. Q.; Tao, H. M.; et al. HPLC-DAD-guided isolation of diversified chaetoglobosins from the coral-associated fungus Chaetomium globosum C2F17. Molecules 2020, 25 (5), 1237. 139. An, L.; Li, C. P.; Zhang, H.; Wang, M. L.; Kong, L. Y.; Yang, M. H. Four cytochalasin alkaloids produced by Chaetomium globosum. Tetrahedron Letters 2020, 61 (19), 151838. 140. Cheng, L.; Zheng, X.; Li, Q.; Wei, M. S.; Chen, C. M.; Zhu, H. C.; et al. Armochaetoglasins J and K: New cytochalasans from Chaetomium globosum. Nat Prod Res 2022, 36 (14), 3603−3609. 141. Li, T.; Wang, Y.; Li, L.; Tang, M.; Meng, Q.; Zhang, C.; et al. New cytotoxic cytochalasans from a plant-associated fungus Chaetomium globosum kz-19. Mar Drugs 2021, 19 (8), 438. 142. Gao, W. X.; Jiang, R.; Zeng, H. X.; Cao, J.; Hu, Z. X.; Zhang, Y. H. Armochaetoglasins L and M, new cytochalasans from an arthropod-derived fungus Chaetomium globosum. Nat Prod Res 2024, 38 (9), 1599−1605. 143. Miao, X.; Hong, L.; Ju, Z.; Liu, H.; Shang, R.; Li, P.; et al. Marchaetoglobins A-D: Four cytochalasans with proangiogenic activity from the marine-sponge-associated fungus Chaetomium globosum 162105. ACS Omega 2024, 9 (20), 22450−22458. 144. Miao, X. X.; Hong, L. L.; Liu, H. Y.; Shang, R. Y.; Jiao, W. H.; Xu, S. H.; et al. Marcytoglobosins A and B, cytochalasans from a marine sponge associated Chaetomium globosum 162105 fungus. Chem Biodivers 2024, 21 (7), e202400832. 145. Takahashi, M.; Koyama, K.; Natori, S. Four new azaphilones from Chaetomium globosum var. flavo-viridae. Chem Pharm Bull 1990, 38 (3), 625−628. 146. Ge, H. M.; Zhang, W. Y.; Ding, G.; Saparpakorn, P.; Song, Y. C.; Hannongbua, S.; et al. Chaetoglobins A and B, two unusual alkaloids from endophytic Chaetomium globosum culture. Chem Commun 2008, 45, 5978−5980. 147. Yamada, T.; Doi, M.; Shigeta, H.; Muroga, Y.; Hosoe, S.; Numata, A.; et al. Absolute stereostructures of cytotoxic metabolites, chaetomugilins A–C, produced by a Chaetomium species separated from a marine fish. Tetrahedron Letters 2008, 49 (26), 4192−4195. 148. Yasuhide, M.; Yamada, T.; Numata, A.; Tanaka, R. Chaetomugilins, new selectively cytotoxic metabolites, produced by a marine fish-derived Chaetomium species. J Antibiot 2008, 61 (10), 615−622. 149. Yamada, T.; Yasuhide, M.; Shigeta, H.; Numata, A.; Tanaka, R. Absolute stereostructures of chaetomugilins G and H produced by a marine-fish-derived Chaetomium species. J Antibiot 2009, 62 (7), 353−357. 150. Muroga, Y.; Yamada, T.; Numata, A.; Tanaka, R. Chaetomugilins I–O, new potent cytotoxic metabolites from a marine-fish-derived Chaetomium species. Stereochemistry and biological activities. Tetrahedron 2009, 65 (36), 7580−7586. 151. Yamada, T.; Muroga, Y.; Tanaka, R. New azaphilones, seco-chaetomugilins A and D, produced by a marine-fish-derived Chaetomium globosum. Mar Drugs 2009, 7 (2), 249−257. 152. Muroga, Y.; Yamada, T.; Numata, A.; Tanaka, R. 11- and 4'-epimers of chaetomugilin A, novel cytostatic metabolites from marine fish-derived fungus Chaetomium globosum. Helv Chim Acta 2010, 93 (3), 542−549. 153. Yamada, T.; Muroga, Y.; Jinno, M.; Kajimoto, T.; Usami, Y.; Numata, A.; et al. New class azaphilone produced by a marine fish-derived Chaetomium globosum. The stereochemistry and biological activities. Bioorg Med Chem 2011, 19 (13), 4106−4113. 154. Borges, W. S.; Mancilla, G.; Guimaraes, D. O.; Duran-Patron, R.; Collado, I. G.; Pupo, M. T. Azaphilones from the endophyte Chaetomium globosum. J Nat Prod 2011, 74 (5), 1182−1187. 155. Yamada, T.; Jinno, M.; Kikuchi, T.; Kajimoto, T.; Numata, A.; Tanaka, R. Three new azaphilones produced by a marine fish-derived Chaetomium globosum. J Antibiot 2012, 65 (8), 413−417. 156. Li, X.; Tian, Y.; Yang, S. X.; Zhang, Y. M.; Qin, J. C. Cytotoxic azaphilone alkaloids from Chaetomium globosum TY1. Bioorg Med Chem Lett 2013, 23 (10), 2945−2947. 157. McMullin, D. R.; Sumarah, M. W.; Blackwell, B. A.; Miller, J. D. New azaphilones from Chaetomium globosum isolated from the built environment. Tetrahedron Letters 2013, 54 (6), 568−572. 158. Youn, U. J.; Sripisut, T.; Park, E. J.; Kondratyuk, T. P.; Fatima, N.; Simmons, C. J.; et al. Determination of the absolute configuration of chaetoviridins and other bioactive azaphilones from the endophytic fungus Chaetomium globosum. Bioorg Med Chem Lett 2015, 25 (21), 4719−4723. 159. Chen, C.; Wang, J.; Zhu, H.; Wang, J.; Xue, Y.; Wei, G.; et al. Chaephilones A and B, two new azaphilone derivatives isolated from Chaetomium globosum. Chem Biodivers 2016, 13 (4), 422−426. 160. Wang, M. H.; Jiang, T.; Ding, G.; Niu, S. B.; Wang, X. W.; Yu, M.; et al. Molecular epigenetic approach activates silent gene cluster producing dimeric bis-spiro-azaphilones in Chaetomium globosum CBS148.51. J Antibiot 2017, 70 (6), 801−804. 161. Sun, C.; Ge, X.; Mudassir, S.; Zhou, L.; Yu, G.; Che, Q.; et al. New glutamine-containing azaphilone alkaloids from deep-sea-derived fungus Chaetomium globosum HDN151398. Mar Drugs 2019, 17 (5), 253. 162. Wang, W.; Yang, J.; Liao, Y. Y.; Cheng, G.; Chen, J.; Cheng, X. D.; et al. Cytotoxic nitrogenated azaphilones from the deep-sea-derived fungus Chaetomium globosum MP4-S01-7. J Nat Prod 2020, 83 (4), 1157−1166. 163. Song, C.; Ding, G.; Wu, G.; Yang, J.; Zhang, M.; Wang, H.; et al. Identification of a unique azaphilone produced by Chaetomium globosum Isolated from Polygonatum sibiricum. Chem Biodivers 2020, 17 (3), e1900744. 164. Fan, Y.; Jiang, C.; Zhang, Y.; Ma, Z.; Li, P.; Guo, L.; et al. Pro-angiogenic new chloro-azaphilone derivatives from the hadal trench-derived fungus Chaetomium globosum YP-106. Front Microbiol 2022, 13, 943452. 165. Fan, Y.; Jiang, C.; Li, P.; Wang, C.; Chen, H. A new chloro-azaphilone derivative with pro-angiogenesis activity from the hadal trench-derived fungus Chaetomium globosum YP-106. J Oceanol Limnol 2022, 41 (3), 1145−1151. 166. Gao, Z. J.; Cao, L. L.; Ren, H. P.; Yu, H.; Wang, Y. Novel chlorinated and nitrogenated azaphilones with cytotoxic activities from the marine algal-derived fungus Chaetomium globosum 2020HZ23. Front Microbiol 2023, 14, 1252563. 167. Li, H. Q.; Li, X. J.; Wang, Y. L.; Zhang, Q.; Zhang, A. L.; Gao, J. M.; et al. Antifungal metabolites from Chaetomium globosum, an endophytic fungus in Ginkgo biloba. Biochem Syst Ecol 2011, 39 (4-6), 876−879. 168. Yan, W.; Ge, H. M.; Wang, G.; Jiang, N.; Mei, Y. N.; Jiang, R.; et al. Pictet-Spengler reaction-based biosynthetic machinery in fungi. Proc Natl Acad Sci U S A 2014, 111 (51), 18138−18143. 169. Xu, G. B.; He, G.; Bai, H. H.; Yang, T.; Zhang, G. L.; Wu, L. W.; et al. Indole alkaloids from Chaetomium globosum. J Nat Prod 2015, 78 (7), 1479−1485. 170. Yan, W.; Cao, L. L.; Zhang, Y. Y.; Zhao, R.; Zhao, S. S.; Khan, B.; et al. New metabolites from endophytic fungus Chaetomium globosum CDW7. Molecules 2018, 23 (11), 2873. 171. Yan, W.; Zhao, S. S.; Ye, Y. H.; Zhang, Y. Y.; Zhang, Y.; Xu, J. Y.; et al. Generation of indoles with agrochemical significance through biotransformation by Chaetomium globosum. J Nat Prod 2019, 82 (8), 2132−2137. 172. Bunbamrung, N.; Intaraudom, C.; Dramae, A.; Boonyuen, N.; Choowong, W.; Rachtawee, P.; et al. Antimalarial and antimicrobial substances from the endophytic fungus Chaetomium globosum BCC71876. Nat Prod Res 2024, (Early Access). 173. Safe, A.; Taylor, A. Sporidesmins. 8. Ovine ill-thrift in Nova Scotia. 3. The characterisation of chetomin a toxic metabolite of Chaetomium cochliodes and Chaetomium globosum. JCS Perkin 1 1972, 4, 472−479. 174. Kikuchi, T.; Kadota, S.; Nakamura, K.; Nishi, A.; Taga, T.; Kaji, T.; et al. Dethio-tetra(methylthio) chetomin, a new antimicrobial metabolite of chaetomium globosum Kinze ex Fr. Structure and partial synthesis from chetomin. Chem Pharm Bull 1982, 30 (10), 3846−3848. 175. Kanokmedhakul, S.; Kanokmedhakul, K.; Phonkerd, N.; Soytong, K.; Kongsaeree, P.; Suksamrarn, A. Antimycobacterial anthraquinone-chromanone compound and diketopiperazine alkaloid from the fungus Chaetomium globosum KMITL-N0802. Planta Med 2002, 68 (9), 834−836. 176. Wang, S.; Li, X. M.; Teuscher, F.; Li, D. L.; Diesel, A.; Ebel, R.; et al. Chaetopyranin, a benzaldehyde derivative, and other related metabolites from Chaetomium globosum. J Nat Prod 2006, 69 (11), 1622−1625. 177. Marmouzi, I.; Faouzi, M. E.; Saidi, N.; Cherrah, Y.; Rehberg, N.; Ebada, S. S.; et al. Bioactive secondary metabolites from Chaetomium globosum, an endophyte from the moroccan plant Avena sativa. Chem Nat Compd 2017, 53 (6), 1208−1211. 178. Wang, F.; Zhao, W.; Zhang, C.; Chang, S.; Shao, R.; Xing, J.; et al. Cytotoxic metabolites from the endophytic fungus Chaetomium globosum 7951. RSC Adv 2019, 9 (28), 16035−16039. 179. Breinholt, J.; Demuth, H.; Heide, M.; Jensen, G. W.; Moller, I. L.; Nielsen, R. I.; et al. Prenisatin (5-(3-methyl-2-butenyl)indole-2,3-dione) an antifungal isatin derivative from Chaetomium globosum. Acta Chem Scand 1996, 50 (5), 433−445. 180. Qin, J. C.; Gao, J. M.; Zhang, Y. M.; Yang, S. X.; Bai, M. S.; Ma, Y. T.; et al. Polyhydroxylated steroids from an endophytic fungus, Chaetomium globosum ZY-22 isolated from Ginkgo biloba. Steroids 2009, 74 (9), 786−790. 181. Ge, H. M.; Zhang, Q. A.; Xu, S. H.; Guo, Z. L.; Song, Y. C.; Huang, W. Y.; et al. Chaetoglocins A-D. Four new metabolites from the endophytic fungus Chaetomium globosum. Planta Med 2011, 77(3), 277−280. 182. Li, H.; Xiao, J.; Gao, Y. Q.; Tang, J. J.; Zhang, A. L.; Gao, J. M. Chaetoglobosins from Chaetomium globosum, an endophytic fungus in Ginkgo biloba, and their phytotoxic and cytotoxic activities. J Agric Food Chem 2014, 62 (17), 3734−3741. 183. Wijeratne, E. M.; Turbyville, T. J.; Fritz, A.; Whitesell, L.; Gunatilaka, A. A. A new dihydroxanthenone from a plant-associated strain of the fungus Chaetomium globosum demonstrates anticancer activity. Bioorg Med Chem 2006, 14 (23), 7917−7923. 184. Tantapakul, C.; Promgool, T.; Kanokmedhakul, K.; Soytong, K.; Song, J.; Hadsadee, S.; Jungsuttiwong, S.; et al. Bioactive xanthoquinodins and epipolythiodioxopiperazines from Chaetomium globosum 7s-1, an endophytic fungus isolated from Rhapis cochinchinensis (Lour.) Mart. Nat Prod Res 2020, 34 (4), 494−502. 185. Nakazawa, T.; Ishiuchi, K.; Sato, M.; Tsunematsu, Y.; Sugimoto, S.; Gotanda, Y.; et al. Targeted disruption of transcriptional regulators in Chaetomium globosum activates biosynthetic pathways and reveals transcriptional regulator-like behavior of aureonitol. J Am Chem Soc 2013, 135 (36), 13446−13455. 186. Brewer, D.; Jerram, W. A.; Taylor , A. The production of cochliodinol and a related metabolite by Chaetomium species. Can J Microbiol 1968, 14, 861−866. 187. Nitao, J. K.; Meyer, S. L. F.; Oliver, J.E.; Schmidt, W. F.; Chitwood, D. J. Isolation of flavipin, a fungus compound antagonistic to plant-parasitic nematodes. 2002, 4, 55−63. 188. Bashyal, B. P.; Wijeratne, E. M. K.; Faeth, S. H.; Gunatilaka, A. A. L. Globosumones A-C, cytotoxic orsellinic acid esters from the sonoran desert endophytic fungus Chaetomium globosum. J Nat Prod 2005, 68 (5), 724−728. 189. Guo, Z. L.; Zheng, J. J.; Cao, F.; Wang, C.; Wang, C. Y. Chemical constituents of the gorgonian-derived fungus Chaetomium globosum. Chem Nat Compd 2017, 53 (1), 199−202. 190. Awad, N. E.; Kassem, H. A.; Hamed, M. A.; El-Feky, A. M.; El-Naggar, M. A. A. Hepatoprotective evaluation and isolation of the major secondary metabolites from the ethyl acetate extract of liquid culture filtrate of Chaetomium globosum. Biomed Pharmacother 2018, 97, 174−180. 191. Yang, S. X.; Zhao, W. T.; Chen, H. Y.; Zhang, L.; Liu, T. K.; Chen, H. P.; et al. Aureonitols A and B, two new C13-polyketides from Chaetomium globosum, an endophytic fungus in Salvia miltiorrhiza. Chem Biodivers 2019, 16 (9), e1900364. 192. Khan, B.; Yan, W.; Wei, S.; Wang, Z.; Zhao, S.; Cao, L.; et al. Nematicidal metabolites from endophytic fungus Chaetomium globosum YSC5. FEMS Microbiol Lett 2019, 366 (14), fnz169. 193. Qi, J. Z.; Wang, D. Z.; Yin, X.; Zhang, Q.; Gao, J. M. New metabolite with inhibitory activity against alpha-glucosidase and alpha-amylase from endophytic Chaetomium globosum. Nat Prod Commun 2020, 15 (7), 1−9. 194. Ji, J. C.; Wei, P. P.; Han, X. Y.; Li, Z. H.; Ai, H. L.; Lei, X. X. Secondary metabolites of the endophytic fungus Chaetomium globosum isolated from Coptis chinensis. Nat Prod Commun 2021, 16 (9), 1−4. 195. Li, X. D.; Li, X. M.; Wang, B. G.; Li, X. Antimicrobial sesterterpenoids with a unique 5/8/6/5 tetracyclic carbon-ring-system and diepoxide polyketides from a deep sea-sediment-sourced fungus Chaetomium globosum SD-347. Org Biomol Chem 2024, 22 (19), 3979−3985. 196. Yang, S. W.; Mierzwa, R.; Terracciano, J.; Patel, M.; Gullo, V.; Wagner, N.; et al. Chemokine receptor CCR-5 inhibitors produced by Chaetomium globosum. J Nat Prod 2006, 69 (7), 1025−1028. 197. Yang, S. W.; Mierzwa, R.; Terracciano, J.; Patel, M.; Gullo, V.; Wagner, N.; et al. Sch 213766, a novel chemokine receptor CCR-5 inhibitor from Chaetomium globosum. J Antibiot 2007, 60 (8), 524−528. 198. Itoh, Y.; Kodama, K.; Furuya, K.; Takahashi, S.; Haneishi, T.; Takiguchi, Y.; et al. A new sesquiterpene antibiotic, heptelidic acid producing organisms, fermentation, isolation and characterization. J Antibiot 1980, 33 (5), 468−473. 199. Zhang, X.; Ye, M.; Gong, Y. J.; Feng, L. M.; Tao, S. J.; Yin, J.; et al. Biotransformation of pseudolaric acid B by Chaetomium globosum. Process Biochem 2011, 46 (10), 2064−2067. 200. Morehouse, N. J.; Clark, T. N.; Kerr, R. G.; Johnson, J. A.; Gray, C. A. Caryophyllene sesquiterpenes from a Chaetomium globosum endophyte of the canadian medicinal plant empetrum nigrum. J Nat Prod 2023, 86 (6), 1615−1619. 201. Zhang, C. Y.; Ji, X.; Gui, X.; Huang, B. K. Chemical constituents from an endophytic fungus Chaetomium globosum Z1. Nat Prod Commun 2013, 8 (9), 1217−1218. 202. Zhang, G.; Zhang, Y.; Qin, J.; Qu, X.; Liu, J.; Li, X.; et al. Antifungal metabolites produced by Chaetomium globosum No.04, an endophytic fungus isolated from Ginkgo biloba. Indian J Microbiol 2013, 53 (2), 175−180. 203. Kamat, S.; Kumari, M.; Sajna, K. V.; Jayabaskaran, C. Endophytic fungus, Chaetomium globosum, associated with marine green alga, a new source of chrysin. Sci Rep 2020, 10 (1), 18726. 204. Qin, J. C.; Zhang, Y. M.; Gao, J. M.; Bai, M. S.; Yang, S. X.; Laatsch, H.; et al. Bioactive metabolites produced by Chaetomium globosum, an endophytic fungus isolated from Ginkgo biloba. Bioorg Med Chem Lett 2009, 19 (6), 1572−1574. 205. McMullin, D. R.; Sumarah, M. W.; Miller, J. D. Chaetoglobosins and azaphilones produced by Canadian strains of Chaetomium globosum isolated from the indoor environment. Mycotoxin Res 2013, 29 (1), 47−54. 206. Zhao, S. S.; Zhang, Y. Y.; Yan, W.; Cao, L. L.; Xiao, Y.; Ye, Y. H. Chaetomium globosum CDW7, a potential biological control strain and its antifungal metabolites. FEMS Microbiol Lett 2017, 364 (3), fnw287. 207. Momesso, L. D.; Kawano, C. Y.; Ribeiro, P. H.; Nomizo, A.; Goldman, G. H.; Pupo, M. T. Chaetoglobosins produced by Chaetomium globosum, endophytic fungus found in association with Viguiera robusta GARDN (Asteraceae). Quim Nova 2008, 31 (7), 1680−1685. 208. Samaga, P. V.; Rai, V. R.; Rai, K. M. L. Production of an antimicrobial cytochalasan by an endophytic Chaetomium globosum HYML55 from Hypericum mysorense and its RNA secondary structure analysis. Chem Ecol 2014, 30 (6), 566−578. 209. Probst, A.; Tamm, C. Biosynthesis of the cytochalasans. Biosynthetic studies on chaetoglobosin A and 19‐O‐acetylchaetoglobosin A. Helvetica Chimica Acta 2004, 64 (7), 2065−2077. 210. Wolfender, J. L.; Queiroz, E. F. New approaches for studying the chemical diversity of natural resources and the bioactivity of their constituents. Chimia 2012, 66 (5), 324−329. 211. Wang, X. Y.; Yan, X.; Fang, M. J.; Wu, Z.; Wang, D.; Qiu, Y. K. Two new cytochalasan derivatives from Chaetomium globosum SNSHI-5, a fungus derived from extreme environment. Nat Prod Res 2017, 31 (14), 1669−1675. 212. Zhang, Y.; Zhu, H.; Ye, Y.; Tang, C. Antifungal activity of chaetoviridin A from Chaetomium globosum CEF-082 metabolites against verticillium dahliae in cotton. Mol Plant Microbe Interact 2021, 34 (7), 758−769. 213. Wang, D.; Zhang, Y.; Li, X.; Pan, H.; Chang, M.; Zheng, T.; et al. Potential allelopathic azaphilones produced by the endophytic Chaetomium globosum TY1 inhabited in Ginkgo biloba using the one strain-many compounds method. Nat Prod Res 2017, 31 (6), 724−728. 214. Piyasena, K.; Wickramarachchi, W.; Kumar, N. S.; Jayasinghe, L.; Fujimoto, Y. Two phytotoxic azaphilone derivatives from Chaetomium globosum, a fungal endophyte isolated from Amaranthus viridis leaves. Mycology 2015, 6 (3-4), 158−160. 215. Ye, Y.; Xiao, Y.; Ma, L.; Li, H.; Xie, Z.; Wang, M.; et al. Flavipin in Chaetomium globosum CDW7, an endophytic fungus from Ginkgo biloba, contributes to antioxidant activity. Appl Microbiol Biotechnol 2013, 97 (16), 7131−7139. 216. Kumar, V. S.; Kumaresan, S.; Tamizh, M. M.; Islam, M. I. H.; Thirugnanasambantham, K. Anticancer potential of NF-kappaB targeting apoptotic molecule "flavipin" isolated from endophytic Chaetomium globosum. Phytomedicine 2019, 61, 152830. 217. Itoh, Y.; Takahashi, S.; Haneishi, T.; Arai, M. Structure of heptelidic acid, a new sesquiterpene antibiotic from fungi. J Antibiot 1980, 33 (5), 525−526. 218. Heard, S. C.; Wu, G.; Winter, J. M. Discovery and characterization of a cytochalasan biosynthetic cluster from the marine-derived fungus Aspergillus flavipes CNL-338. J Antibiot 2020, 73 (11), 803−807. | - |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/97029 | - |
| dc.description.abstract | 從台灣金門和彰化海岸採集的濱海藥用植物－馬氏濱藜 (Atriplex maximowcziana Makino) 中，分離並純化出1,534株真菌。接著以紙錠擴散法 (disk-diffusion method)，從真菌株粗萃物中篩選具有抗人體致病菌－金黃色葡萄球菌 (Staphylococcus aureus YC981)、白色念珠菌 (Candida albicans SC5314)、大腸桿菌 (Escherichia coli DH5α) 及新型隱球菌 (Cryptococcus neoformans H99) 等致病菌活性的化合物，結果發現，其中39株在1 mg/mL的濃度下具有顯著的抗菌活性，進一步挑選具開發潛力的真菌株進行後續研究，首先以DNA定序確認真菌株的分類位階，已初步完成32株真菌的鑑種，並由後續各種活性平台的評估，例如：抗病毒、抗發炎、抗血管新生、細胞毒性等，發現Curvularia intermedia Km0855 和Chaetomium globosum Km1226具有抑制第四型人類皰疹病毒活性，其抑制百分比分別為4%和17%；C. intermedia Km0855、Fusarium sp. Km1163、C. globosum Km1226、Alternaria sp. Km1934、Cochliobolus sp. Km1956、Fusarium sp. Km 2117和Fusarium sp. Km 2277具有抑制人類內皮源細胞血管新生活性，其抑制百分比分別為1%、<0%、<0%、4%、<0%、2%和4%；在小鼠神經膠質BV-2細胞上，Neocamarosporium sp. Km1910和Cochliobolus sp. Km1996並無細胞毒性，且具有顯著抑制NO產生的活性，其抑制百分比分別為35%和78%，藉由這些數據的呈現，決定以一株多化合物策略 (one strain-many compounds, OSMAC) 對其中具潛力的100株真菌株進行小量培養，再針對其發酵所含之代謝產物以液相層析串聯質譜儀 (LC-MS/MS) 進一步分析，並使用MZmine、全球天然物社群分子網絡 (GNPS) 和Cytoscape建立可視化和註釋非靶向質譜數據的分子網絡 (MN)，繪製複雜樣本的化學空間圖，以促進有潛力真菌株和分子的發現，依序將C. globosum Km1226、 C. intermedia Km0855和Stemphylium lycopersici Km1578以OSMAC策略進行大量培養，再針對其發酵液所含之代謝產物以管柱 (CC) 和高效液相層析儀 (HPLC) 進行分析、分離與純化，接著以核磁共振儀 (NMR) 作為主要的工具確認化合物的分子結構，搭配質譜 (MS)、紅外光譜 (IR)、結晶繞射 (X-ray) 和紫外光譜 (UV) 等數據佐證結構的正確性，共得到24種聚酮體 (ployketide)、4種大環內脂 (macrocyclic lactone) 和7種生物鹼 (alkaloid) ，包含3個新化合物aureonitol C (1) 和mollipilins G和 H (2 和 3)，以及32個已知化合物aureonitol (4)、mollipilins A和F (5和6)、aureonitol A (7)、chaetoglobosins A–F (8–13)、aureochaeglobosins B和C (14和15)、dihydrocoarctatin (16)、coarctatin (17)、chaetoviridin A (18)、chaetomugilin A (19)、chaetomugilin D (20)、11-epichaetomugilin A (21)、12β-hydroxychaetoviridin C (22)、(+)-(11S, 15R)-11-hydroxycurvularin (23)、(+)-(11R, 15R)-11-hydroxycurvularin (24)、(S)-dehydrocurvularin (25)、curvularin (26)、lunatin (27)、rheoemodin (28)、3,11α,12β,13β,16-pentahydroxy-11,12-dihydroperylen-6(13H)-one (29)、altersolanol A (30)、auxarthrol C (31)、infectopyrone (32)、stemphyloxin Ⅱ (33)、stemphyloxin Ⅰ (34) 和stemphyperylenol (35)，其中化合物5 在小鼠神經膠質BV-2細胞上具有顯著抑制NO產生的效果，其半抑制濃度 (IC50) 為0.7 ± 0.1 μM；化合物8在人類大腸直腸癌HCT-116細胞上具有顯著細胞毒性，其 IC50 為3.0 ± 0.1 μM；化合物11在人類內皮源細胞上具有顯著抗血管新生活性，其IC50 為0.8 ± 0.3 μM；化合物23–25在EBV上具有抑制效果，其EC50值介於1.6至3.5 μM，且化合物23的選擇指數 (SI) 為8.5；化合物29在Staphylococcus aureus NEWMAN具有顯著的抑制作用，其最低抑菌濃度測定 (MIC) 值為4.0 μg/mL。 | zh_TW |
| dc.description.abstract | 1,534 fungal strains were isolated from the littoral medicinal herb Atriplex maximowicziana Makino collected from Kinmen and Changhua coast, Taiwan. Using disk-diffusion method for the screening of antimicrobial activities from the ethyl acetate extract of the bioactivities of fungal strains against Staphylococcus aureus YC981, Escherichia coli DH5α, Candida albicans SC5314 and Cryptococcus neoformans H99. The 39 fungal strains were found to exhibit significant antimicrobial activities at a concentration of 1 mg/mL, and selected the more potential fungal strains for in-depth study. Firstly, by using polymerase chain reaction to determine the fungal strains DNA sequences, 32 fungal strains already have been determined their taxonomy. In order to develop leading drug candidates, various biological activities (anti-virus, anti-inflammatory activity, anti-angiogenesis and cytotoxicity etc.) tests were practiced. Curvularia intermedia Km0855 and Chaetomium globosum Km1226 exhibited significant human herpesvirus 4 (HHV-4) inhibitory activity with the percentage of inhibition were 4% and 17%, respectively; C. intermedia Km0855, Fusarium sp. Km1163, C. globosum Km1226, Alternaria sp. Km1934, Cochliobolus sp. Km1956, Fusarium sp. Km 2117 and Fusarium sp. Km 2277 exhibited significant anti-angiogenesis activity in human endothelial progenitor cells with the percentage of inhibition were 1%、<0%、<0%、4%、<0%、2% and 4%, respectively; Neocamarosporium sp. Km1910 and Cochliobolus sp. Km1996 showed no cytotoxicity toward microglial BV-2 cells, but exhibited significant inhibitory activity of LPS-induced NO production with the percentage of inhibition were 35% and 78%, respectively. Therefore, potential 100 fungal strains were investigated intensively by applying OSMAC strategy. The secondary metabolites contained in the fermentation were further analyzed using liquid chromatography tandem mass spectrometry (LC-MS/MS). The MS2 data were generated by MZmine, Global Natural Product Social Molecular Networking (GNPS) and Cytoscape to build molecular networking (MN) for visualizing and annotating non-targeted mass spectrometry data. It was used to map the chemical space of complex samples to facilitate the discovery of potential fungal strain and new molecule. The fungal strain C. globosum Km1226, C. intermedia Km0855 and Stemphylium lycopersici Km1578 were further cultured by OSMAC strategy for scale-up, resulted in the isolation of compounds 1–35. Their structures were determined by spectroscopic analysis as 24 polyketides, 4 macrocyclic lactone and 7 alkaloids, including three previously undescribed C13-polyketides, namely aureonitol C (1), mollipilins G and H (2 and 3), along with thirty-two known compounds, aureonitol (4)、mollipilins A and F (5 and 6), aureonitol A (7), chaetoglobosins A–F (8–13), aureochaeglobosins B and C (14 and 15), dihydrocoarctatin (16), coarctatin (17), chaetoviridin A (18), chaetomugilin A (19), chaetomugilin D (20), 11-epichaetomugilin A (21), 12β-hydroxychaetoviridin C (22), (+)-(11S,15R)-11-hydroxycurvularin (23), (+)-(11R,15R)-11-hydroxycurvularin (24), (S)-dehydrocurvularin (25), curvularin (26), lunatin (27), rheoemodin (28), 3,11α,12β,13β,16-pentahydroxy-11,12-dihydroperylen-6(13H)-one (29), altersolanol A (30), auxarthrol C (31), infectopyrone (32), stemphyloxin Ⅱ (33), stemphyloxin I (34), stemphyperylenol (35). Among these, 6 exhibited significant LPS-induced NO production inhibitory activity with an IC50 value of 0.7 ± 0.1 μM in microglial BV-2 cells; 8 showed potent cytotoxic activity with an IC50 value of 3.0 ± 0.1 μM in HCT-116; 11 exhibited significant anti-angiogenesis activity with an IC50 value of 0.8 ± 0.3 μM in human endothelial progenitor cells; 23–25 showed good antiviral activities against EBV with the EC50 values of 1.6 to 3.5 μM, especially selectivity index of 23 was 8.5; 29 exhibited significant antimicrobial activity with minimum inhibitory concentration value of 4.0 μg/mL against Staphylococcus aureus NEWMAN. | en |
| dc.description.provenance | Submitted by admin ntu (admin@lib.ntu.edu.tw) on 2025-02-25T16:33:22Z No. of bitstreams: 0 | en |
| dc.description.provenance | Made available in DSpace on 2025-02-25T16:33:22Z (GMT). No. of bitstreams: 0 | en |
| dc.description.tableofcontents | 口試委員會審定書 i
中文摘要 iii 英文摘要 v 圖 次 xi 表 次 xiv 縮寫表 xv 第一章 緒論與研究目的 1 1.1 緒論 1 1.2 研究目的 9 第二章 文獻回顧 17 2.1 球毛殼菌 (Chaetomium globosum) 分類學與來源介紹 17 2.2 球毛殼菌 (Chaetomium globosum) 真菌成分 17 第三章 實驗結果 62 3.1 真菌二次代謝產物萃取與分離流程 62 3.1.1 Chaetomium globosum Km1226之培養與分離流程 62 3.2 一株多化合物策略運用與潛力二次代謝產物開發流程 66 3.2.1 Chaetomium globosum Km1226之基於培養方式改變 66 3.2.2 Chaetomium globosum Km1226之基於培養成分修改 68 3.2.3 Chaetomium globosum Km1226之添加表觀遺傳修飾劑 70 3.2.4具潛力菌株Curvularia intermedia Km0855之應用 75 3.3 天然物結構解析 84 3.3.1 Aureonitol C (1) 之結構解析 84 3.3.2 Mollipilin G (2) 之結構解析 93 3.3.3 Mollipilin H (3) 之結構解析 102 3.3.4 Aureonitol (4) 之結構數據 108 3.3.5 Mollipilin A (5) 之結構數據 109 3.3.6 Mollipilin F (6) 之結構數據 110 3.3.7 Aureonitol A (7) 之結構數據 111 3.3.8 Chaetoglobosin A (8) 之結構數據 112 3.3.9 Chaetoglobosin B (9) 之結構數據 113 3.3.10 Chaetoglobosin C (10) 之結構數據 114 3.3.11 Chaetoglobosin D (11) 之結構數據 115 3.3.12 Chaetoglobosin E (12) 之結構數據 116 3.3.13 Chaetoglobosin F (13) 之結構數據 117 3.3.14 Aureochaeglobosin B (14) 之結構數據 118 3.3.15 Aureochaeglobosin C (15) 之結構數據 119 3.3.16 Dihydrocoarctatin (16) 之結構數據 119 3.3.17 Coarctatin (17) 之結構數據 120 3.3.18 Chaetoviridin A (18) 之結構數據 120 3.3.19 Chaetomugilin A (19) 之結構數據 121 3.3.20 Chaetomugilin D (20) 之結構數據 121 3.3.21 11-Epichaetomugilin A (21) 之結構數據 122 3.3.22 12β-Hydroxychaetoviridin C (22) 之結構數據 122 3.3.23 (+)-(11S,15R)-11-Hydroxycurvularin (23) 之結構數據 123 3.3.24 (+)-(11R,15R)-11-Hydroxycurvularin (24) 之結構數據 124 3.3.25 (S)-Dehydrocurvularin (25) 之結構數據 125 3.3.26 Curvularin (26) 之結構數據 126 3.3.27 Lunatin (27) 之結構數據 127 3.3.28 Rheoemodin (28) 之結構數據 128 3.3.29 3,11α,12β,13β,16-Pentahydroxy-11,12-dihydroperylen-6(13H)-one (29) 之結構數據 129 3.3.30 Altersolanol A (30) 之結構數據 129 Figure 86. 化合物30之碳譜 (methanol-d4, 150 MHz) 130 3.3.31 Auxarthrol C (31) 之結構數據 130 Figure 87. 化合物31之氫譜 (DMSO-d6, 600 MHz) 130 3.3.32 Infectopyrone (32) 之結構數據 131 Figure 89. 化合物32之氫譜 (pyridine-d5, 600 MHz) 131 3.3.33 Stemphyloxin Ⅱ (33) 之結構數據 132 Figure 91. 化合物33之氫譜 (chloroform-d, 600 MHz) 132 3.3.34 Stemphyloxin Ⅰ (34) 之結構數據 133 3.3.35 Stemphyperylenol (35) 之結構數據 134 3.4 化合物1-3之物理數據 135 3.5 化合物活性平台測試 136 3.5.1 一氧化氮抑制與細胞存活率之實驗結果 136 3.5.2 抗血管增生試驗 139 3.5.3 抗病毒之實驗結果 141 第四章 實驗部分 143 4.1 儀器設備與試劑 143 4.1.1 化合物之物理性質測定儀器 143 4.1.2 高效能液相層析系統 143 4.1.3 管柱層析膠體 144 4.1.3 薄層層析片 144 4.1.4 試劑與溶劑 144 4.1.5 培養基 144 4.2 實驗材料 145 4.2.1 真菌材料 145 4.2.2 菌種DNA鑑定 145 4.2.4 真菌菌株篩選 148 4.3 分子網絡建立 150 4.4 真菌擴量培養與成分分離 152 4.4.1 培養基配製 152 4.4.2 Chaetomium globosum Km1226液態發酵液萃取 (by flask) 152 4.4.3 Chaetomium globosum Km1226液態發酵液萃取 (by bottle) 153 4.4.4 Chaetomium globosum Km1226固態發酵萃取 153 4.4.5 Chaetomium globosum Km1226液態發酵液萃取 (OSMAC) 153 4.4.6 Curvularia intermedia Km0855液態發酵液萃取 (by flask) 154 4.4.7 Curvularia intermedia Km0855液態發酵液萃取 (OSMAC) 154 4.4.8 Stenphylium lycopersici Km1578液態發酵液萃取 (by flask) 154 4.4.9 Chaetomium globosum Km1226液態發酵液 (by flask) 之成分分離與純化 155 4.4.11 Chaetomium globosum Km1226固態發酵萃取之成分分離與純化 158 4.4.12 Chaetomium globosum Km1226液態發酵液萃取 (OSMAC) 之成分分離與純化 160 4.4.13 Curvularia intermedia Km0855液態發酵液萃取 (by flask) 之成分分離與純化 161 4.4.14 Curvularia intermedia Km0855液態發酵液萃取 (OSMAC) 之成分分離與純化 162 4.4.15 Stemphylium lycopersici Km1578液態發酵液萃取之成分分離與純化 163 4.5 抗發炎活性評估 165 4.5.1 細胞培養 165 4.5.2 Griess reagent assay 165 4.5.3 MTT assay 165 4.6 抗血管增生活性評估 166 4.6.1 細胞培養 166 4.7 抗病毒活性評估 166 4.7.1 細胞培養 167 第五章 討論 168 第六章 參考文獻 171 | - |
| dc.language.iso | zh_TW | - |
| dc.subject | 內生真菌 | zh_TW |
| dc.subject | 一株多化合物策略 | zh_TW |
| dc.subject | 分子網絡 | zh_TW |
| dc.subject | 抗發炎 | zh_TW |
| dc.subject | 抗血管新生 | zh_TW |
| dc.subject | 抗病毒 | zh_TW |
| dc.subject | 馬氏濱藜 | zh_TW |
| dc.subject | antivirus | en |
| dc.subject | Atriplex maximowcziana | en |
| dc.subject | endophytic fungi | en |
| dc.subject | OSMAC | en |
| dc.subject | molecular networking | en |
| dc.subject | anti‑inflammation | en |
| dc.subject | anti-angiogenesis | en |
| dc.title | 濱海藥用植物馬氏濱藜 (Atriplex maximowicziana) 之衍生真菌株的活性成分和天然物之策略開發 | zh_TW |
| dc.title | Bioactive constituents from littoral medicinal herb Atriplex maximowicziana-derived fungi and the strategic development of natural products | en |
| dc.type | Thesis | - |
| dc.date.schoolyear | 113-1 | - |
| dc.description.degree | 博士 | - |
| dc.contributor.oralexamcommittee | 李慶國;蕭哲志;張麗冠;陳日榮;季偉瓊;王士維 | zh_TW |
| dc.contributor.oralexamcommittee | Ching-Kuo Lee;George Hsiao;Li-Kwan Chang;Jih-Jung Chen;Wei-Chiung Chi;Shih-Wei Wang | en |
| dc.subject.keyword | 馬氏濱藜,內生真菌,一株多化合物策略,分子網絡,抗發炎,抗血管新生,抗病毒, | zh_TW |
| dc.subject.keyword | Atriplex maximowcziana,endophytic fungi,OSMAC,molecular networking,anti‑inflammation,anti-angiogenesis,antivirus, | en |
| dc.relation.page | 197 | - |
| dc.identifier.doi | 10.6342/NTU202500731 | - |
| dc.rights.note | 同意授權(全球公開) | - |
| dc.date.accepted | 2025-02-17 | - |
| dc.contributor.author-college | 生命科學院 | - |
| dc.contributor.author-dept | 漁業科學研究所 | - |
| dc.date.embargo-lift | 2025-02-26 | - |
| 顯示於系所單位： | 漁業科學研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-113-1.pdf | 14.83 MB | Adobe PDF | 檢視/開啟 |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。